Hisamitsu Pharmaceutical CoHTSUY 85 Net Margin % is 12.30% as of Nov. 2025, which is 0% below its 10-year median of 12.32. GuruFocus rates HTSUY with a GF Score™ of 85/100 and a GF Value™ of $5.41 (Significantly Undervalued). Among 956 Drug Manufacturers companies, Hisamitsu Pharmaceutical Co ranks better than 69.56% on this metric.
The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Net Margin % or its related term are showing as below:
HTSUY'
s Net Margin % Range Over the Past 10 Years
Min: 8.04 Med: 12.32 Max: 13.98
Current: 11.75
HTSUY's Net Margin % is ranked better than 69.56% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs HTSUY: 11.75
Hisamitsu Pharmaceutical Co (OTCPK:HTSUY) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Hisamitsu Pharmaceutical Co Net Margin % Related Terms
Hisamitsu Pharmaceutical Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co (HTSUY) has a Net Margin % of 12.30% as of Nov. 2025. Net margin is the ratio of total net income to net sales. View historical data on Hisamitsu Pharmaceutical Co and its competitors. This is near median its historical median of 12.32. Over the past decade, Hisamitsu Pharmaceutical Co's Net Margin % has ranged from 8.04 to 13.98. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #291 out of 956 companies in the Drug Manufacturers industry, placing it in the top 30.4%.
Is Hisamitsu Pharmaceutical Co's Net Margin % too high?
Hisamitsu Pharmaceutical Co's current Net Margin % of 12.30% is near median its 10-year median of 12.32. Over the past 10 years, this metric has ranged from a low of 8.04 to a high of 13.98. The Drug Manufacturers industry median Net Margin % is 5.56. Hisamitsu Pharmaceutical Co's value of 12.30% is 121.2% above this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #291 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #291 out of 956 companies for Net Margin %. This puts Hisamitsu Pharmaceutical Co in the upper half of its industry. The industry median Net Margin % is 5.56. Hisamitsu Pharmaceutical Co's value of 12.30% is 121.2% above this benchmark. Historically, Hisamitsu Pharmaceutical Co's own Net Margin % has ranged from 8.04 to 13.98 over the past decade. While the company's 10-year median is 12.32 vs. the industry median of 5.56, Hisamitsu Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current Net Margin % of 12.30% is 121.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current Net Margin % is 12.30%, which is near median its own 10-year median of 12.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co (HTSUY) is currently considered Significantly Undervalued. The stock's GF Value™ is $5.41, compared to a current price of $2.94 — trading 45.7% below its estimated fair value. The current Net Margin % is 12.30%, which is near median its 10-year median of 12.32 and 121.2% above the Drug Manufacturers industry median of 5.56. Hisamitsu Pharmaceutical Co's overall GF Score™ is 85/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (HTSUY), the current Net Margin % is 12.30% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (HTSUY) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be undervalued.
The current stock price of $2.94 is trading 45.7% below its estimated GF Value™ of $5.41.
GuruFocus considers Hisamitsu Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for HTSUY:
Net Margin %: 12.30% (near median its 10-year median of 12.32)
GF Value™: $5.41 vs. price of $2.94 (45.7% below fair value)
Industry Position: 121.2% above the Drug Manufacturers median (#291 of 956)
No single metric tells the full story. See the HTSUY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
85GF Score
Get the complete analysis for HTSUY
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HTSUY has been successfully added to your 
